These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 19043680)

  • 1. Effect of epoetin zeta for correction of renal anemia in hemodialysis patients with thalassemia minor.
    Kumchev E; Koytchev R; Dimitrakov D; Stavrev P; Tsochev G; Siebert-Weigel M
    Adv Ther; 2008 Dec; 25(12):1375-8. PubMed ID: 19043680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
    Krivoshiev S; Wizemann V; Czekalski S; Schiller A; Pljesa S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A;
    Adv Ther; 2010 Feb; 27(2):105-17. PubMed ID: 20369312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia.
    Baldamus C; Krivoshiev S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A
    Adv Ther; 2008 Nov; 25(11):1215-28. PubMed ID: 18931828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epoetin omega for treatment of anemia in maintenance hemodialysis patients.
    Sikole A; Spasovski G; Zafirov D; Polenakovic M
    Clin Nephrol; 2002 Mar; 57(3):237-45. PubMed ID: 11924756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis.
    Więcek A; Ahmed I; Scigalla P; Koytchev R
    Adv Ther; 2010 Dec; 27(12):941-52. PubMed ID: 20972656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis.
    Haag-Weber M; Vetter A; Thyroff-Friesinger U;
    Clin Nephrol; 2009 Nov; 72(5):380-90. PubMed ID: 19863881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
    Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
    Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the therapeutic efficacy of epoetin beta and epoetin alfa in maintenance phase hemodialysis patients.
    Loughnan A; Ali GR; Abeygunasekara SC
    Ren Fail; 2011; 33(3):373-5. PubMed ID: 21401367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Can anemia be corrected in hemodialysis patients with thalassaemia minor? ].
    Di Iorio B; Guastaferro P; Gironda A; Marano V; Morrongiello L; Cillo N; Zito B; Nigro F; Frieri A; Rubino R; Bellizzi V
    G Ital Nefrol; 2002; 19(5):552-9. PubMed ID: 12439845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilar epoetin zeta in nephrology - a single-dialysis center experience.
    Lonnemann G; Wrenger E
    Clin Nephrol; 2011 Jan; 75(1):59-62. PubMed ID: 21176751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H; Mimura T; Honda N
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does treatment of renal anemia with recombinant erythropoietin influence oxidative stress in hemodialysis patients?
    Sommerburg O; Grune T; Hampl H; Riedel E; Ehrich JH; Siems WG
    Clin Nephrol; 2000 Feb; 53(1 Suppl):S23-9. PubMed ID: 10746802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia.
    Thanakitcharu P; Siriwiwatanakul N
    J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose tailoring strategies in haemodialysis patients: a discussion of case histories.
    Kleophas W
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi31-6. PubMed ID: 15958825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia.
    Krivoshiev S; Todorov VV; Manitius J; Czekalski S; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 May; 24(5):1407-15. PubMed ID: 18394266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-every-2-weeks and once-weekly epoetin beta regimens: equivalency in hemodialyzed patients.
    Mircescu G; Gârneată L; Ciocâlteu A; Golea O; Gherman-Căprioară M; Capsa D; Mota E; Gusbeth-Tatomir P; Ghenu A; Bălută S; Constantinovici N; Covic AC
    Am J Kidney Dis; 2006 Sep; 48(3):445-55. PubMed ID: 16931218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of once-weekly intravenous administration of epoetin-beta as a maintenance treatment for anemia in Japanese hemodialysis patients: a multicenter, open-label clinical study.
    Shigematsu T; Takami H; Shimizu T; Shimoyama H; Kim S; Hirose S; Sakai T; Kono T; Mochizuki T; Nishio K; Degawa H; Motomiya Y
    Ther Apher Dial; 2008 Dec; 12(6):469-74. PubMed ID: 19140845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of anti-erythropoietin antibodies in hemodialysis patients without clinical signs of pure red cell aplasia. Comparison between hypo- and normoresponsive patients treated with epoetins for renal anemia.
    Stoffel MP; Haverkamp H; Kromminga A; Lauterbach KW; Baldamus CA
    Nephron Clin Pract; 2007; 105(2):c90-8. PubMed ID: 17164586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.